The endoscopic treatment of gastric antral vascular ectasia (GAVE) is a relatively uncharted field with few reliable techniques available for the time being.

As is well known, assessed from a histological standpoint, GAVE consists of dilated and tortuous capillaries in the mucosal layer, often associated with intraluminal thrombi and accompanied by dilated and tortuous submucosal veins, without significant inflammation. The typical location of these capillaries is in the gastric antrum, with variations in overall shape and extent. The exact pathophysiological pathway is relatively unknown. Several hypotheses have been proposed, including mechanical stress due to the relatively higher pressure in the antrum, hormone imbalance mostly related to hypergastrinemic states, and an association with tyrosine kinase inhibitors. \[1 - 3\] Yet none of the above appears to have any direct implication regarding our current therapeutic options. However, the association with chronic kidney disease, advanced liver disease, systemic sclerosis, and metabolic syndrome is unquestionable, suggesting that optimizing management of these chronic diseases should improve the outcome of secondary conditions such as GAVE.

As we currently understand the problem, it appears that we have hit a deadlock regarding our treatment options, as the available methods are few and far from perfect.

No pharmacological treatment has proven to be effective in this setting, with only modest endeavors published in this field. The lack of a proper understanding of the pathophysiology might be a feasible explanation. Estrogen-progesterone regimens for cirrhotic patients with GAVE \[4\] were tried more than 20 years ago, but the data were not strong enough for validation and no significant subsequent studies were performed. An association between proton pump inhibitors (PPIs) and GAVE has also been proposed (acid suppression leading to hypogastrinemia) \[5, 6\], but discontinuing PPIs can hardly be called a therapeutic option.

Surgery is a delicate option in GAVE, because most patients carry the burden of multiple and severe comorbidities. Unfortunately, the risk/benefit analysis can often be tilted towards undesirable events, and operating remains a viable option only for emergency refractory cases.

Therefore, the only viable solutions we have for GAVE are concentrated in the field of endoscopic therapy. The array of available options can be divided into two groups, based on layer penetration: superficial (action limited to the mucosa) and deep (including submucosa). Superficial techniques act mostly on the mucosal layer and are represented by argon plasma coagulation (APC) and radiofrequency ablation (RFA). Cryotherapy and Nd:YAG laser therapy have been largely abandoned due to relative ineffectiveness, high complication rates, and availability issues. The only deep submucosal technique available is endoscopic band ligation (EBL).

Judging by the histological appearance of GAVE, with dilated and tortuous submucosal veins, along with extensive mucosal lesions, one could empirically imply that reaching a more profound layer should generate better outcomes. However, APC has long been the staple of GAVE treatment. APC generates good immediate results, with therapeutic success ranging between 70% and 90%, although recurrent bleeding and further interventions were frequently required, ranging from a reasonable 35% to an inefficient 78.9% \[7 - 11\]. Only recently has the tide appeared to be shifting towards EBL, after first being used as salvage therapy in a case of APC refractory GAVE bleeding \[12\]. Since then, multiple papers have been published on EBL describing relatively favorable outcomes. One retrospective...
comparison between EBL and APC showed a significantly lower recurrent bleeding rate in favor of EBL (8% vs. 68%) [13]. Another similar study showed that therapeutic success after EBL was obtained in 100% of cases, compared to 48% for APC [14]. A prospective comparative study in a pediatric population also hinted at the superiority of EBL, requiring fewer and shorter sessions and a significantly decreased need for blood transfusions [15]. Up to this point, there is only one randomized controlled study of EBL and APC in treatment of gastric antral and fundal vascular ectasia in cirrhotic patients, suggesting the superiority of EBL in terms of number of sessions and blood transfusion units needed [16]. Other previous reports, including a previous analysis performed by the same group, followed the same trend [17, 18]. The current article published by Eccles et al. [19] regarding long-term follow-up of patients with GAVE treated with EBL, further strengthens the case for expanding use of EBL in GAVE, with high initial success rate and relatively low recurrent bleeding rates, albeit in a small sample.

There are several theoretical advantages of EBL, when compared to the other endoscopic techniques, which of course need further validation. Per se, EBL is cheaper than APC, and it is widely available. It also appears that fewer procedures are needed, therefore further reducing costs. Also, long-term fibrosis in the submucosa should, at least theoretically, reduce reoccurrence rates by preventing dilatation of new small venous tracts. Not least, EBL requires less experience, and can be performed by less experienced endoscopists, with instant confirmation of procedure success, which can, as a consequence, expand the availability of the method.

The trend of recent research, strongly enforced by the current article, combined with the inherent and theoretical advantages of EBL is promising. However, do we have enough data to proclaim the supremacy of EBL in GAVE? There are only a few prospective studies comparing APC and EBL, but the results favor the latter. Expanding on the current dataset could give rise to a new gold standard in the field, sooner rather than later.

Competing interests

None

References